NCT02441686 2026-01-13
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
6 trialsNCT02375555 2024-10-01
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01731886 2020-02-05
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
Columbia University
Phase 4 Completed
NCT01251172 2017-09-28
RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT02288741 2014-11-11
DSMM-II
WiSP Wissenschaftlicher Service Pharma GmbH
Phase 3 Completed
NCT00299780 2007-04-24
Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization.
Massachusetts General Hospital
Phase 1 Completed